相关实验视频

Updated: Sep 18, 2025

Author Spotlight: Development of Simplified CRISPR-Based Tests for Rapid Detection of Infectious Diseases

Author Spotlight: Development of Simplified CRISPR-Based Tests for Rapid Detection of Infectious Diseases

Published on: August 16, 2024

准SARS-CoV-2RNA依赖RNA聚合酶的库马林衍生物BPR2-D2:来自细胞和酶研究的证据

Wen-Fang Tang¹, Hui-Ping Tsai², Yuan-Fan Chin²

¹Research Center for Emerging Viral Infections, College of Medicine, Chang Gung University, Kweishan, Taoyuan, Taiwan.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

|June 21, 2025

概括

氨酸衍生物BPR2-D2通过破坏病毒RNA合成和调节RNA依赖RNA聚合酶 (RdRp) 活性,有效抑制多种SARS-CoV-2变异. 这种化合物与雷梅西维尔具有协同作用,将其定位为有前途的抗病毒药物.

科学领域:

病毒学病毒学
药物发现药物发现药物发现
分子生物学分子生物学

背景情况:

由于SARS-CoV-2的快速突变,需要持续开发药物,以提高疗效和安全性.
库马林衍生物BPR2-D2已证明具有抗流感和广泛的RNA病毒抑制作用.

研究的目的:

为了评估BPR2-D2对SARS-CoV-2变种的抗病毒活性.
研究BPR2-D2的作用机制,重点研究其与SARS-CoV-2RNA依赖RNA聚合酶 (RdRp) 的相互作用.
评估与remdesivir结合使用的BPR2-D2的协同作用潜力.

主要方法:

包括分子对接,动态模拟和具有约束力的自由能量计算在内的分析.
基于细胞的测试以评估抗病毒活性,细胞因子调节和协同效应.
在体外以酶为基础的RdRp报告员测定.

主要成果:

在纳米分子度下,BPR2-D2对多种SARS-CoV-2变体表现出强烈的活性.
BPR2-D2破坏了病毒RNA和蛋白质合成,并减轻了促炎性细胞因子.
在和体外研究表明,BPR2-D2与remdesivir相比,对SARS-CoV-2 RdRp具有更好的结合亲和力,并且在结合时表现出协同抑制.

结论:

BPR2-D2是一种强大的SARS-CoV-2抑制剂,通过调节RdRp功能而起作用.
该化合物与雷梅西维尔具有协同活性,增强病毒RNA合成的抑制.
BPR2-D2代表了一种有前途的重用小分子抗病毒剂,用于SARS-CoV-2治疗.

关键词:

这是一种抗病毒药物.在BPR2-D2中使用BPR2-D2.非核酸抑制剂的非核酸抑制剂这是一种RdRp抑制剂.严重急性呼吸系统综合征冠状病毒2 有协同效应的效应.

更多相关视频

Visualization of SARS-CoV-2 using Immuno RNA-Fluorescence In Situ Hybridization

Visualization of SARS-CoV-2 using Immuno RNA-Fluorescence In Situ Hybridization

Published on: December 23, 2020

In Vitro Selection of Aptamers to Differentiate Infectious from Non-Infectious Viruses

In Vitro Selection of Aptamers to Differentiate Infectious from Non-Infectious Viruses

Published on: September 7, 2022

相关概念视频

Eukaryotic RNA Polymerases

Eukaryotic RNA Polymerases

RNA Polymerase (RNAP) is conserved in all animals, with bacterial, archaeal, and eukaryotic RNAPs sharing significant sequence, structural, and functional similarities. Among the three eukaryotic RNAPs, RNA Polymerase II is most similar to bacterial RNAP in terms of both structural organization and folding topologies of the enzyme subunits. However, these similarities are not reflected in their mechanism of action.
All three eukaryotic RNAPs require specific transcription factors, of which the...

Bacterial RNA Polymerase

Bacterial RNA Polymerase

Unlike eukaryotes, bacteria use a single RNA Polymerase (RNAP) to transcribe all genes. The different subunits of bacterial RNAPhave distinct functions. The multisubunit structure of the bacterial RNAP helps the enzyme to maintain catalytic function, facilitate assembly, interact with DNA and RNA, and self-regulate its activity.
In most genes, the transcription site is a single base present upstream of the coding sequence. Though RNAP is a catalytically efficient enzyme, it does not recognize...

Transcription Initiation

Transcription Initiation

Initiation is the first step of transcription in eukaryotes. Prokaryotic RNA Polymerase (RNAP) can bind to the template DNA and start transcribing. On the other hand, transcription in eukaryotes requires additional proteins, called transcription factors, to first bind to the promoter region in the DNA template. This binding helps recruit the specific RNAP that can assemble on the DNA and start transcription.
The promoters and enhancers and their accessory proteins allow tight regulation of...